Astena Holdings upgrades full-year operating profit forecast — chemical/pharma firm beats
Toyo Keizai reported Astena Holdings (アステナホールディングス) raised its full-year operating profit guidance modestly, with the chemical and pharmaceutical segments outperforming. In a session dominated by large-cap declines, small/mid-cap profit upgrades like this stand out as a counter-cyclical signal. Astena's diverse ingredient portfolio (cosmetics, pharma APIs) makes it a read on both domestic consumption and export demand.
Read at Toyo Keizai Online ↗